Drug Profile
Aspirin/ramipril/simvastatin - Ferrer
Alternative Names: Acetylsalicylic-acid/ramipiril/simvastatin; Cardiovascular Polypill; Polypill - Ferrer; SincroniumLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Ferrer
- Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Heterocyclic bicyclo compounds; Naphthalenes; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cardiovascular disorders
Most Recent Events
- 08 Sep 2021 No development reported - Phase-III for Cardiovascular disorders in Paraguay, Italy, Brazil, Argentina, Spain (PO) (Ferrer website, September 2021)
- 15 Mar 2019 Launched for Cardiovascular disorders in Mexico (PO) (Ferrer Website, February 2019)
- 08 Nov 2018 Chemical structure information added